KCM
PTLA

Karp Capital Management’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Karp Capital Management’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-350
Closed -$15K – 310
2015
Q3 		$15K Buy
+350
New +$16.9K 0.01% 249

Other funds holding PTLA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Karp Capital Management's PTLA Position: Q4 2015 in Review

Karp Capital Management sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q4 2015, closing a stake of 350 shares — an estimated $15K sold.

Karp Capital Management first reported a position in PTLA in Q3 2015 and held it in 1 quarter. The position peaked at $15K in Q3 2015. 190 funds tracked by Wall St. Rank hold PTLA as of Q4 2015.

  • Karp Capital Management reported no remaining Portola Pharmaceuticals, Inc. position as of Q4 2015 after selling out during the quarter.
  • Karp Capital Management sold 350 Portola Pharmaceuticals, Inc. shares in Q4 2015, an estimated $15K.
  • Karp Capital Management first reported a position in Portola Pharmaceuticals, Inc. in Q3 2015 and held it in 1 quarter.
  • Karp Capital Management's Portola Pharmaceuticals, Inc. position peaked at $15K in Q3 2015.
  • 190 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q4 2015.

Based on Karp Capital Management's 13F filing for Q4 2015, filed 9 Feb 2016.